Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Leukemia

Free Subscription 24.11.2025 1 Acta Haematol 2 Am J Clin Pathol 7 Ann Hematol 1 Biochem Biophys Res Commun 3 Blood 3 BMC Cancer 13 Br J Haematol 1 Cancer 1 Cancer Res 1 Cell 7 Int J Hematol 2 J Clin Oncol 7 Leuk Lymphoma 1 Leuk Res 8 Leukemia 1 Oncogene 1 Oncol Rep

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Haematol

1. WU J, Li J, Yin J, Huang D, et al
   Imatinib Treatment in Primary Acute Basophilic Leukemia with FIP1L1-PDGFRalpha Rearrangement: A Case Report.
   Acta Haematol. 2025 Nov 14:1-10. doi: 10.1159/000549406.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

2. JASIM A, Lee W, Ma H, Quirk E, et al
   CD9: Differential expression of normal bone marrow cellular components and leukemic myeloid blasts.
   Am J Clin Pathol. 2025;164:694-703.
   PubMed         Abstract available
   
   
3. CHAKRABORTY SR, Bickford MA, Smuliac NA, Tonseth KA, et al
   IGL::CCND1 detected by optical genome mapping revises diagnosis of a B-cell lymphoma.
   Am J Clin Pathol. 2025 Sep 10:aqaf096. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Ann Hematol

4. YANG H, Xu Y, Zhang X, Wang Y, et al
   Serum miR-493-3p as a diagnostic biomarker and epigenetic regulator targeting DPY30 in pediatric acute lymphoblastic leukemia.
   Ann Hematol. 2025 Nov 18. doi: 10.1007/s00277-025-06681.
   PubMed         Abstract available
   
   
5. DING W, Zhao J, Wang Z, Liu Y, et al
   Combination therapy based on venetoclax overcomes resistance to all-trans retinoic acid and arsenic trioxide in a variant acute promyelocytic leukemia with TNRC18::RARA fusion.
   Ann Hematol. 2025 Nov 17. doi: 10.1007/s00277-025-06658.
   PubMed        
   
   
6. YU L, Jiang Q
   Successful fatherhood of males with tyrosine kinase inhibitor-resistant chronic myeloid leukemia taking olverembatinib.
   Ann Hematol. 2025 Nov 14. doi: 10.1007/s00277-025-06722.
   PubMed         Abstract available
   
   
7. YUAN X, Wu Y, Wang Y, Wu J, et al
   Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT.
   Ann Hematol. 2025;104:5359-5369.
   PubMed         Abstract available
   
   
8. MAQHUZU PN, Bocuk D, Boelz S, Hosseini SK, et al
   Epidemiology of chronic lymphocytic leukaemia in Germany: A retrospective analysis of administrative claims data.
   Ann Hematol. 2025;104:5237-5256.
   PubMed         Abstract available
   
   
9. KONG J, Tian Z, Deng DX, Mo XD, et al
   Treatment of transplantation-associated thrombotic microangiopathy with iptacopan: two cases report.
   Ann Hematol. 2025;104:5537-5541.
   PubMed         Abstract available
   
   
10. YE F, Wang L, Qian Y, Deng W, et al
    Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy.
    Ann Hematol. 2025;104:5507-5512.
    PubMed         Abstract available
    
    

    
    Biochem Biophys Res Commun

11. MU R, Pei X, Xu N, Liu B, et al
    Regorafenib promotes ferroptosis in acute myeloid leukemia by upregulating NOX4.
    Biochem Biophys Res Commun. 2025;792:152981.
    PubMed         Abstract available
    
    

    
    Blood

12. RAJ R, Catueno S, Gibson A, McCall D, et al
    FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.
    Blood. 2025;146:2608-2611.
    PubMed         Abstract available
    
    
13. BUECHNER J, Poetschger U, Bader P, Yesilipek MA, et al
    Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.
    Blood. 2025 Nov 19:blood.2025030951. doi: 10.1182/blood.2025030951.
    PubMed         Abstract available
    
    
14. PARISI X, Loghavi S
    NPM1-mutated acute myeloid leukemia with marked erythroid and megakaryocytic differentiation.
    Blood. 2025;146:2612.
    PubMed        
    
    

    
    BMC Cancer

15. HUANG Q, Ling Z, Zhang W, Zhang M, et al
    Prognostic significance of cytogenetic and molecular features in pediatric acute myeloid leukemia: a meta-analysis.
    BMC Cancer. 2025;25:1774.
    PubMed         Abstract available
    
    
16. SORDINI E, Ciurlia E, Zanella A, Fogliardi B, et al
    Decitabine-mediated DNA methylation dynamics at pericentromeric satellite 2 repeats.
    BMC Cancer. 2025;25:1778.
    PubMed         Abstract available
    
    
17. MAHDI AN, Elsaid AM, Mohammed MA, Madkour MM, et al
    Genetic insights into acute lymphoblastic leukemia: the role of MDR1 and IL18 polymorphisms in Egyptian children.
    BMC Cancer. 2025;25:1792.
    PubMed         Abstract available
    
    

    
    Br J Haematol

18. BERTOLI D, Giupponi C, Rossi G, D'Adda M, et al
    ET occurring in NPM1-mutated AML during molecular complete remission: A further potential evolution of a complex disease.
    Br J Haematol. 2025;207:2153-2157.
    PubMed         Abstract available
    
    
19. LI Y, Jin L, Liu W, Liu Y, et al
    Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.
    Br J Haematol. 2025 Sep 16. doi: 10.1111/bjh.70097.
    PubMed         Abstract available
    
    
20. METZLER M, Branford S, Hijiya N, Sakamoto K, et al
    An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia.
    Br J Haematol. 2025;207:1782-1788.
    PubMed         Abstract available
    
    
21. HILLS RK
    Seeing something new or with new eyes?
    Br J Haematol. 2025;207:2231-2232.
    PubMed         Abstract available
    
    
22. DAM M, Centanni M, Centanni D, Friberg LE, et al
    Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study.
    Br J Haematol. 2025;207:1920-1929.
    PubMed         Abstract available
    
    
23. BOUDRY A, Goursaud L, Lebon D, Dumezy F, et al
    Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia.
    Br J Haematol. 2025;207:1953-1961.
    PubMed         Abstract available
    
    
24. YING S, Yang L, Zhang L, Hong R, et al
    The role of CBFbeta::MYH11 fusion gene in acute lysis pneumopathy: A dual impact on risk and prognosis.
    Br J Haematol. 2025;207:1944-1952.
    PubMed         Abstract available
    
    
25. MEYER JA, Xirenayi S, Werner J, Turakulov R, et al
    Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.
    Br J Haematol. 2025;207:1938-1943.
    PubMed         Abstract available
    
    
26. TAMAI M, Komatsu C, Kagami K, Kasai S, et al
    A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model.
    Br J Haematol. 2025;207:1842-1854.
    PubMed         Abstract available
    
    
27. HOANG T, Cheung MC, Juurlink DN, Chan KKW, et al
    Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2025;207:1893-1901.
    PubMed         Abstract available
    
    
28. YU F, Yu X, Hu X, Jiang E, et al
    Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025 Aug 26. doi: 10.1111/bjh.70102.
    PubMed         Abstract available
    
    
29. SHIMONI A, Peczynski C, Labopin M, Dominietto A, et al
    Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working
    Br J Haematol. 2025;207:2041-2048.
    PubMed         Abstract available
    
    
30. ROKKANEN R, Aarnivala H, Huhtaniska S, Palmu S, et al
    Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.
    Br J Haematol. 2025;207:1912-1919.
    PubMed         Abstract available
    
    

    
    Cancer

31. OK CY, Natu A, Daneshpajouhnejad P, Fathalla LA, et al
    Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly.
    Cancer. 2025;131:e70176.
    PubMed         Abstract available
    
    

    
    Cancer Res

32. ERIKSSON J, Zheng S, Popa M, Bao J, et al
    Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia.
    Cancer Res. 2025 Nov 21. doi: 10.1158/0008-5472.CAN-24-3753.
    PubMed         Abstract available
    
    

    
    Cell

33. LEWIS AC, Gruber E, Franich R, Armstrong J, et al
    Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia.
    Cell. 2025 Nov 19:S0092-8674(25)01233-4. doi: 10.1016/j.cell.2025.
    PubMed         Abstract available
    
    

    
    Int J Hematol

34. OYA S, Maehiro Y
    Thrombophagocytosis by myeloid blasts in acute myeloid leukemia with biallelic CEBPA mutations.
    Int J Hematol. 2025 Nov 21. doi: 10.1007/s12185-025-04116.
    PubMed        
    
    
35. SHIMADA T, Takahata A, Tanaka K, Toyota S, et al
    Efficacy and safety of venetoclax-based regimens versus intensive chemotherapy in older adults with newly diagnosed acute myeloid leukemia: a single-center retrospective study.
    Int J Hematol. 2025 Nov 17. doi: 10.1007/s12185-025-04111.
    PubMed         Abstract available
    
    
36. LIU X, Zhong J, Luo M, Gu X, et al
    Chronic myeloid leukemia with atypical transcript e8a2: a case report and literature review.
    Int J Hematol. 2025 Nov 15. doi: 10.1007/s12185-025-04088.
    PubMed         Abstract available
    
    
37. BAHASHWAN AS
    A meta-analysis of diagnostic challenges in Ph-like ALL at baseline: early detection strategies for personalized therapeutic interventions.
    Int J Hematol. 2025;122:803-814.
    PubMed         Abstract available
    
    
38. SCHWENEKER K, Lenk M, Kern W, Haferlach C, et al
    Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real world cohort.
    Int J Hematol. 2025;122:835-842.
    PubMed         Abstract available
    
    
39. HOSONO N, Tomiyama Y, Emori N, Isogaya K, et al
    Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study.
    Int J Hematol. 2025;122:824-834.
    PubMed         Abstract available
    
    
40. DOI H, Akiyama H, Matsui T, Shiogama K, et al
    Andrographolide drives dual apoptosis and ferroptosis via caspase-3 and FACL4 in T-ALL cell lines.
    Int J Hematol. 2025;122:843-855.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

41. SHARMAN JP, Liu B, Wang DY, Leow CC, et al
    Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.
    J Clin Oncol. 2025 Nov 21:JCO2502231. doi: 10.1200/JCO-25-02231.
    PubMed        
    
    
42. CLIFF ERS, Lew TE, Simon F, Hilal T, et al
    Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.
    J Clin Oncol. 2025 Nov 21:JCO2501695. doi: 10.1200/JCO-25-01695.
    PubMed        
    
    

    
    Leuk Lymphoma

43. LATAGLIATA R, Carmosino I, Di Veroli A, Scalzulli E, et al
    Hemoglobin changes during long-lasting frontline treatment with Tyrosine-Kinase inhibitors in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2025 Nov 17:1-6. doi: 10.1080/10428194.2025.2586816.
    PubMed         Abstract available
    
    
44. CHO C, Redd R, Haydu JE, Johnson PC, et al
    Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis.
    Leuk Lymphoma. 2025 Nov 18:1-5. doi: 10.1080/10428194.2025.2581717.
    PubMed        
    
    
45. CALVILLO CD, Cardenas Castro V, Shim KG, Arribas M, et al
    NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients.
    Leuk Lymphoma. 2025 Nov 19:1-7. doi: 10.1080/10428194.2025.2586084.
    PubMed         Abstract available
    
    
46. SUN Y, Aviv H
    Neuroendocrine transdifferentiation of aggressive B-cell leukemia/lymphoma post CAR-T therapy.
    Leuk Lymphoma. 2025 Nov 19:1-4. doi: 10.1080/10428194.2025.2589375.
    PubMed        
    
    
47. LAGANA A, Scalzulli E, Carmosino I, Bisegna ML, et al
    Early predictive factors of molecular relapse in chronic phase-chronic myeloid leukemia (CP-CML) patients after tyrosine kinase inhibitor (TKI) discontinuation.
    Leuk Lymphoma. 2025 Nov 20:1-5. doi: 10.1080/10428194.2025.2591778.
    PubMed        
    
    
48. MOHAMMED SALEH MF, Nasiri A, Kotb A, Ahmed SO, et al
    The emerging role of immunotherapy in improving outcomes in Down syndrome - associated acute lymphoblastic leukemia: an insightful review.
    Leuk Lymphoma. 2025 Nov 20:1-8. doi: 10.1080/10428194.2025.2590596.
    PubMed         Abstract available
    
    
49. GANJU N, Sharma M, Dhawan R, Oberoi G, et al
    Effect of tyrosine kinase inhibitors on sperm parameter and pituitary gonadal axis in males with chronic myeloid leukemia: a prospective cohort study.
    Leuk Lymphoma. 2025 Nov 20:1-8. doi: 10.1080/10428194.2025.2584688.
    PubMed         Abstract available
    
    

    
    Leuk Res

50. TIAN S, Wang H, Parikh SA, Liu Y, et al
    Genomic profiling reveals molecular heterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL).
    Leuk Res. 2025;160:108133.
    PubMed         Abstract available
    
    

    
    Leukemia

51. CASTAGNETTI F, Breccia M, Abruzzese E, Bassan R, et al
    Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.
    Leukemia. 2025 Nov 18. doi: 10.1038/s41375-025-02796.
    PubMed         Abstract available
    
    
52. SUI P, Li Y, Hong J, Delma CR, et al
    Oncogenic activation of EVC/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.
    Leukemia. 2025 Nov 17. doi: 10.1038/s41375-025-02803.
    PubMed         Abstract available
    
    
53. KADIRKAMANATHAN R, Georgiadis C, Kloos A, Joshi A, et al
    Base edited "universal" donor CAR T-cell strategies for acute myeloid leukaemia.
    Leukemia. 2025;39:2978-2987.
    PubMed         Abstract available
    
    
54. ELEFTHERIOU M, Russell J, Tzelepis K
    Epitranscriptomic advances in normal and malignant hematopoiesis.
    Leukemia. 2025;39:2848-2857.
    PubMed         Abstract available
    
    
55. PURHONEN M, Tatun M, Luukkainen K, Hung K, et al
    Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.
    Leukemia. 2025;39:2968-2977.
    PubMed         Abstract available
    
    
56. KARAKASLAR EO, Argiro EM, Struckman NE, Shirali Hz R, et al
    Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.
    Leukemia. 2025;39:2916-2925.
    PubMed         Abstract available
    
    
57. BAKEWELL J, Moorman AV, Ryan SL
    DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum.
    Leukemia. 2025;39:2835-2847.
    PubMed         Abstract available
    
    
58. MIRAKI-MOUD F, Ariza-McNaughton L, KoKo T, Othman J, et al
    Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.
    Leukemia. 2025;39:2895-2906.
    PubMed         Abstract available
    
    

    
    Oncogene

59. MA X, Li Y, Sun W, Lou J, et al
    Super-enhancer-associated long noncoding RNA lnc-SPI1U mediates SPI1 feedback regulation by interacting with HNRNPH1 and HNRNPF.
    Oncogene. 2025;44:4626-4638.
    PubMed         Abstract available
    
    

    
    Oncol Rep

60. SUWANWONG Y, Ploensil P
    Role of histone deacetylases in blood cancer: Exploring peptide?based inhibitors as therapeutic strategies for leukemia treatment (Review).
    Oncol Rep. 2026;55:17.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.